PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
Science Immunology · 26.05.2023 · 8 (83)
DOI: 10.1126/sciimmunol.abn6173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 26.05.2023. Verfasst von Mandy van Gulijk und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Skin Neoplasms. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Despite the clinical success of immune checkpoint blockade (ICB), in certain cancer types, most patients with cancer do not respond well. Furthermore, in patients for whom ICB is initially successful, this is often short-lived because of the development of resistance to ICB. The mechanisms underlying primary or secondary ICB resistance are incompletely understood. Here, we identified preferential activation and enhanced suppressive capacity of regulatory T cells (T reg cells) in αPD-L1 therapy–resistant solid tumor–bearing mice. T reg cell depletion reversed resistance to αPD-L1 with concomitant expansion of effector T cells. Moreover, we found that tumor-infiltrating T reg cells in human patients with skin cancer, and in patients with non–small cell lung cancer, up-regulated a suppressive transcriptional gene program after ICB treatment, which correlated with lack of treatment response. αPD-1/PD-L1–induced PD-1 + T reg cell activation was also seen in peripheral blood of patients with lung cancer and mesothelioma, especially in nonresponders. Together, these data reveal that treatment with αPD-1 and αPD-L1 unleashes the immunosuppressive role of T reg cells, resulting in therapy resistance, suggesting that T reg cell targeting is an important adjunct strategy to enhance therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
- Erasmus MC Cancer Institute, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
- Laboratory of Immunoregulation and Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium.
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands.
- Department of Biomics, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
- JJP Biologics, Warsaw, Poland.
ORCID-Profile: Mandy van Gulijk, Anneloes van Krimpen, Sjoerd Schetters, Mike Eterman, Marit van Elsas, Joanne Mankor, Larissa Klaase, Marjolein de Bruijn, Tim van Tienhoven, Wilfred van Ijcken, Louis Boon, Johan van der Schoot, Martijn Verdoes, Ferenc Scheeren, Sjoerd H van der Burg, Bart N Lambrecht, Ralph Stadhouders, Thorbald van Hall
Zitieren
APA
van Gulijk, M., van Krimpen, A., Schetters, S., Eterman, M., van Elsas, M., Mankor, J., Klaase, L., de Bruijn, M., van Nimwegen, M., van Tienhoven, T., van Ijcken, W., Boon, L., van der Schoot, J., Verdoes, M., Scheeren, F., van der Burg, S. H., Lambrecht, B. N., Stadhouders, R., Dammeijer, F., …, & van Hall, T. (2023). PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Science Immunology, 8(83). https://doi.org/10.1126/sciimmunol.abn6173
Vancouver
van Gulijk M, van Krimpen A, Schetters S, Eterman M, van Elsas M, Mankor J, et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Science Immunology. 2023;8(83). doi:10.1126/sciimmunol.abn6173
BibTeX
@article{vanGulijk2023,
author = {van Gulijk, Mandy and van Krimpen, Anneloes and Schetters, Sjoerd and Eterman, Mike and van Elsas, Marit and Mankor, Joanne and Klaase, Larissa and de Bruijn, Marjolein and van Nimwegen, Menno and van Tienhoven, Tim and van Ijcken, Wilfred and Boon, Louis and van der Schoot, Johan and Verdoes, Martijn and Scheeren, Ferenc and van der Burg, Sjoerd H and Lambrecht, Bart N and Stadhouders, Ralph and Dammeijer, Floris and Aerts, Joachim and van Hall, Thorbald},
title = {PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance},
journal = {Science Immunology},
year = {2023},
volume = {8},
number = {83},
doi = {10.1126/sciimmunol.abn6173}
}
EUVIMED